The Biomarkers Task Force initiative was made possible by the:
Steering Committee
Chair
Lisa H. Butterfield, PhD
University of Pittsburgh
Co-Chairs
|
Mary L. Disis, MD
University of Washington
|
Bernard A. Fox, PhD
Earle A. Chiles Research Institute
|
|
Samir N. Khleif, MD
Georgia Health Sciences
|
Francesco Marincola, MD
AbbVie |
FDA Liason
Raj K. Puri, MD, PhD
U.S. Food and Drug Administration
WG 1 - Immunologic Monitoring, Assay Standardization & Validation
Co-Chairs
|
Guiseppe V. Masucci, MD, PhD
Karolinska University Hospital, Solna
|
Magdalena Thurin, PhD
National Cancer Institute
|
Members
|
John Alvarez, MD, PhD
Janssen R&D
|
Alessandra Cesano, MD, PhD
NanoString Inc.
|
Kevin K. Dobbin, PhD
University of Georgia
|
|
Rachael Hawtin, PhD
Nodality
|
Sylvia Janetzki, MD
Zellnet Consulting, Inc.
|
Ilan Kirsch, MD
Adaptive Technologies
|
|
Raj K. Puri, MD, PhD
FDA, CBER
|
Paul Robbins, PhD
MedImmune
|
Senthamil R. Selvan, PhD
Omni Array Biotechnology
|
|
Howard Z. Streicher, MD
National Cancer Institute - Cancer Therapy Evaluation Program
|
Zhe Zhang, PhD
BioHealth Innovation
|
|
WG 2 - New Developments in Biomarker Assays & New Technologies
Chair
Jianda Yuan, MD
Merck
Members
|
Raphael Clynes, MD, PhD
Bristol-Myers Squibb
|
Periklis Foukas, MD, PhD
University Hospital of Lausanne
|
Bernard A. Fox, PhD
Earle A. Chiles Research Institute
|
|
Alexandre Harari, PhD
University Hospital of Lausanne
|
Priti Hegde, PhD
Genentech
|
Thomas O. Kleen, PhD
Epiontis GmbH
|
|
Pia Kvistborg, PhD
Netherlands Cancer Institute
|
Christina Maccalli, PhD
Department of Translational Medicine,
Sidra Medical and Research Department
|
Holden T. Maecker, PhD
Stanford University Medical Center
|
|
Harlan Robins, PhD
Adaptive Biotechnologies Corporation
|
Wenru Song, MD, PhD
AstraZeneca
|
Edward C. Stack, PhD
PerkinElmer
|
|
Ena Wang, MD
Sidra Medical and Research Center
|
Theresa L. Whiteside, PhD
University of Pittsburgh Cancer Institute
|
Yingdong Zhao, PhD
National Cancer Institute
|
|
Heinz Zwierzina, MD
Innsbruck Medical University
|
|
|
WG 3 - Assessment of Immune Regulation & Modulation Systematically (High Throughput Approaches)
Chair
David F. Stroncek, MD
National Institutes of Health
Members
|
Michael Cannarile, PhD
Roche Innovation Center Zurich
|
Madhav Dhodapkar, MD
Yale University
|
Tim Greten, MD
National Institutes of Health
|
|
David Kaufman, MD, PhD
Merck Research Laboratories
|
Peter P. Lee, MD
City of Hope
|
Francesco Marincola, MD
Sidra Medical and Research Center
|
|
Sergio Rutella, MD, PhD
Nottingham Trent University
|
Barbara Seliger, PhD
Martin Luther University Halle-Wittenberg
|
Janet Siebert, MS
CytoAnalytics
|
|
Giorgio Trinchieri, MD
National Cancer Institute
|
|
|
WG 4 - Prediction of Clinical Outcome Based on Baseline Measures
Chair
Sacha Gnjatic, PhD
Icahn School of Medicine at Mount Sinai
Members
|
Vincenzo Bronte, MD
University of Verona
|
Laura Rosa Brunet, DSc
Immodulon Therapeutics Ltd
|
Marcus Butler, MD
Princess Margaret Cancer Centre
|
|
Mary L. Disis, MD
University of Washington
|
Jerome Galon, MD
INSERM - Cordeliers Research Center
|
Leif G. Hakansson, MD, PhD
Cancer Drug Development Forum
|
|
Brent A. Hanks, MD, PhD
Duke University Medical Center
|
Vaios Karanikas, PhD
Roche Innovation Center Zurich
|
Samir N. Khleif, MD
Georgia Cancer Center
|
|
John M. Kirkwood, MD
University of Pittsburgh
|
Lance Miller, PhD
Wake Forest School of Medicine
|
Dolores J. Schendel, PhD
Medigene Immunotherapies GmbH
|
|
Isabelle Tanneau, MSc
ImmuneID
|
Jon M. Wigginton, MD
Macrogenics, Inc.
|
|